Chai Discovery has partnered with argenx to leverage AI for antibody discovery, marking a significant advancement in the life sciences sector.
Chai Discovery, based in San Francisco, has formed a collaboration with argenx, providing the immunology firm with early access to its generative AI platform aimed at de novo antibody discovery. This partnership is notable as it is the fourth disclosed collaboration for Chai within a span of seven months, following similar agreements with major pharmaceutical companies like Eli Lilly, Pfizer, and Novartis. The financial specifics of the agreement remain undisclosed.
The collaboration allows argenx researchers to utilize Chai's platform to computationally design antibody candidates without relying on existing templates, targeting unspecified areas in immunology. This approach aligns with Chai's innovative generative capabilities, particularly with its flagship model, Chai-3, which is designed to create three-dimensional molecular structures across various biological entities. Chai-3 is an advancement over its predecessor, Chai-2, which was recognized for achieving significantly higher experimental hit rates in antibody design compared to earlier methods.
Chai Discovery's recent partnerships come at a pivotal time, as the company recently raised $400 million in a Series C funding round, increasing its valuation to approximately $3.8 billion. This strategic timing suggests that the argenx collaboration is part of a broader commercial strategy aimed at expanding Chai's footprint in the pharmaceutical sector while enhancing its funding narrative through established relationships with industry leaders.
The implications of this partnership could be substantial, as it not only diversifies argenx's discovery toolkit but also highlights the growing trend of integrating AI technologies in drug discovery, which may lead to more efficient and effective therapeutic developments in the future.